CBC Group Completes Strategic Acquisition of UCB's Mature Product Portfolio in China
Published on 08/07/2025 at 18:07 | prnewswire.co.uk
CBC Group and Mubadala acquire UCB's mature neurology and allergy business in China for US$680 million.New company is named NeuroGen Pharma, led by an experienced management team with a strong track record in the biopharma industry.Strategic acquisition under CBC's buyout strategy expected to drive significant value creation and positive patient outcomes through CBC's proven investor-operator approach and solution.View original content:https://www.prnewswire.co.uk/news-releases/cbc-group-completes-strategic-acquisition-of-ucbs-mature-product-portfolio-in-china-302319018.html
en | boerse | 67942968 |
